<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00036686</url>
  </required_header>
  <id_info>
    <org_study_id>MCC-13021</org_study_id>
    <secondary_id>NCI-5348</secondary_id>
    <secondary_id>NCI-P02-0214</secondary_id>
    <secondary_id>0104</secondary_id>
    <nct_id>NCT00036686</nct_id>
  </id_info>
  <brief_title>Isoflavones in Treating Women Who Have Breast Cancer and Are Planning to Undergo Mastectomy or Lumpectomy</brief_title>
  <official_title>A Clinical Trial of the Action of Isoflavones in Breast Neoplasia: Administration Prior to Mastectomy or Lumpectomy-A Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>H. Lee Moffitt Cancer Center and Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>H. Lee Moffitt Cancer Center and Research Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Eating a diet rich in soy foods may slow the progression of some types of cancer.&#xD;
      Isoflavones are compounds found in soy food that may slow the growth of breast cancer cells&#xD;
      and prevent further development of breast cancer.&#xD;
&#xD;
      PURPOSE: Randomized pilot trial to study the effectiveness of isoflavones in preventing&#xD;
      further development of breast cancer in women who are planning to undergo mastectomy or&#xD;
      lumpectomy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the effect of soy protein isolate (isoflavones) on modulation of intermediate&#xD;
           endpoint biomarkers (such as cell proliferation, apoptosis, and steroid hormones) in&#xD;
           women planning to undergo mastectomy or lumpectomy for breast cancer.&#xD;
&#xD;
        -  Determine the effect of soy protein isolate on serum isoflavone levels in these&#xD;
           patients.&#xD;
&#xD;
        -  Correlate changes in serum isoflavones with changes in cell proliferation, apoptosis,&#xD;
           and hormonal levels in patients treated with this therapy.&#xD;
&#xD;
        -  Correlate the changes in cell proliferation and apoptosis with hormonal markers in&#xD;
           patients treated with this therapy.&#xD;
&#xD;
      OUTLINE: This is a randomized, placebo-controlled, double-blind study. Patients are&#xD;
      stratified according to the phase of the menstrual cycle at time of biopsy and time of&#xD;
      surgery (follicular phase [i.e., during first 7 days of menstrual cycle] vs luteal phase&#xD;
      [i.e., after day 7 of the menstrual cycle]). Patients are randomized to one of two treatment&#xD;
      arms.&#xD;
&#xD;
        -  Arm I: Patients receive oral soy protein isolate twice daily and oral multivitamins once&#xD;
           daily.&#xD;
&#xD;
        -  Arm II:Patients receive oral placebo twice daily and oral multivitamins once daily.&#xD;
&#xD;
      In both arms, treatment continues for 2-4 weeks depending on time from study entry to planned&#xD;
      surgical procedure.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 106 patients (53 per treatment arm) will be accrued for this&#xD;
      study within 18 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    low accrual&#xD;
  </why_stopped>
  <start_date>December 2002</start_date>
  <completion_date type="Actual">March 2003</completion_date>
  <primary_completion_date type="Actual">March 2003</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Occurrence of Soy Protein Isolate Effect</measure>
    <time_frame>1 Year</time_frame>
    <description>Determine the effect of soy protein isolate (isoflavones) on modulation of intermediate endpoint biomarkers (such as cell proliferation, apoptosis, and steroid hormones) in women planning to undergo mastectomy or lumpectomy for breast cancer.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Occurrence of Effect on Serum Isoflavone Levels</measure>
    <time_frame>1 Year</time_frame>
    <description>Determine the effect of soy protein isolate on serum isoflavone levels in these patients.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Soy protein isolate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administration Prior to Mastectomy or Lumpectomy.&#xD;
Patients receive oral soy protein isolate twice daily and oral multivitamins once daily.&#xD;
Treatment continues for 2-4 weeks depending on time from study entry to planned surgical procedure.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Administration Prior to Mastectomy or Lumpectomy.&#xD;
Patients receive oral placebo twice daily and oral multivitamins once daily.&#xD;
Treatment continues for 2-4 weeks depending on time from study entry to planned surgical procedure.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Soy protein isolate</intervention_name>
    <description>Arm I: Patients receive oral soy protein isolate twice daily and oral multivitamins once daily.</description>
    <arm_group_label>Soy protein isolate</arm_group_label>
    <other_name>isoflavones</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Arm II: Patients receive oral placebo twice daily and oral multivitamins once daily.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Undergoing breast biopsy for any stage breast cancer&#xD;
&#xD;
               -  No excisional biopsy&#xD;
&#xD;
               -  At least one core biopsy block must contain carcinoma&#xD;
&#xD;
          -  Definitive surgery (mastectomy or lumpectomy) planned for 2-4 weeks after registration&#xD;
             to this study&#xD;
&#xD;
          -  Hormone receptor status:&#xD;
&#xD;
               -  Not specified&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Sex:&#xD;
&#xD;
          -  Female&#xD;
&#xD;
        Menopausal status:&#xD;
&#xD;
          -  Premenopausal&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  No known prior hepatic disease&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  No known prior renal disease&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Fertile patients must use effective non-hormonal contraception&#xD;
&#xD;
          -  No other prior malignancy except nonmelanoma skin cancer&#xD;
&#xD;
          -  No known prior thyroid disease&#xD;
&#xD;
          -  No adherence to vegan diet or other special dietary requirements that would preclude&#xD;
             study participation&#xD;
&#xD;
          -  No allergy to study agent&#xD;
&#xD;
          -  No obesity (body mass index greater than 32)&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  No concurrent birth control pills or other hormonal therapy&#xD;
&#xD;
          -  No concurrent thyroid hormone replacement medications&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  More than 30 days since prior antibiotics&#xD;
&#xD;
          -  More than 4 weeks since prior soy products&#xD;
&#xD;
          -  No routine consumption of greater than 40 mg of soy/day&#xD;
&#xD;
          -  No other concurrent nutritional supplements, including modular supplements of other&#xD;
             isoflavones&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nagi B. Kumar, PhD, RD, FADA</last_name>
    <role>Study Chair</role>
    <affiliation>H. Lee Moffitt Cancer Center and Research Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CCOP - Western Regional, Arizona</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85006-2726</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H. Lee Moffitt Cancer Center and Research Institute</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612-9497</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Coastal Hematology and Oncology, P.C. - Savannah</name>
      <address>
        <city>Savannah</city>
        <state>Georgia</state>
        <zip>31406</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. John's Regional Health Center</name>
      <address>
        <city>Springfield</city>
        <state>Missouri</state>
        <zip>65804-2263</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hulston Cancer Center at Cox Medical Center South</name>
      <address>
        <city>Springfield</city>
        <state>Missouri</state>
        <zip>65807</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Comprehensive Cancer Center at Our Lady of Mercy Medical Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10466</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Merit Care Hospital</name>
      <address>
        <city>Fargo</city>
        <state>North Dakota</state>
        <zip>58122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2012</verification_date>
  <study_first_submitted>May 13, 2002</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>September 21, 2012</last_update_submitted>
  <last_update_submitted_qc>September 21, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 24, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage I breast cancer</keyword>
  <keyword>stage II breast cancer</keyword>
  <keyword>stage IIIA breast cancer</keyword>
  <keyword>stage IIIB breast cancer</keyword>
  <keyword>stage IIIC breast cancer</keyword>
  <keyword>recurrent breast cancer</keyword>
  <keyword>stage IV breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

